
Nordea Investment Management AB significantly increased its stake in Illumina, Inc. by 2,792.2% in Q4, acquiring an additional 911,843 shares and holding a total of 944,500 shares valued at $124.15 million. This move highlights strong institutional confidence amid mixed analyst ratings, with some raising price targets while others remain cautious. Illumina reported solid Q4 earnings, beating estimates with $1.35 EPS and 5% revenue growth, and set a 2026 EPS guidance of 5.05-5.20. The company remains a key player in life sciences, focusing on genetic analysis technologies, attracting both institutional and insider activity.